NE-DESIGN-DATA
23.5.2017 14:02:47 CEST | Business Wire | Press release
Design Data, a leader in 3D steel detailing and Building Information Modeling (BIM) software, announced that the Steel Construction Institute (SCI) has recently assessed Design Data’s SDS/2 2016 software for connection design.
SDS/2 takes a uniquely intelligent approach in its connection design by considering framing conditions and erectability, automatically performing clash prevention as a part of its connection design. In addition, SDS/2 can value engineer the connections on a project, helping users to design the most economical connections to fabricate and erect.
SCI’s process involved reviewing connection design output in depth for each connection type: partial depth end plates, fin plates, column splices, beam splices, bracing connections, and bolted moment connections (end plates). Each connection was reviewed in detail for numerical correctness for the specific arrangement, but also to demonstrate that important principles common to all connections were correctly implemented.
SCI’s assessment was made in accordance with Eurocode 3: Design of steel structures, BS EN 1993, and the relevant UK National Annexes. Additionally, the “Green Books” were used as reference documents, being referenced in the U.K. National Annex and the de facto standard in the U.K.
“Achieving SCI Assessed status is a key advantage for us entering the U.K. and European markets,” said Damon Scaggs, president of Design Data. “With incorporating European design codes for the first time into SDS/2 — which already implements American, Canadian and Australian design codes — it was important to subject the software to the rigorous and extensive testing SCI conducted. This will help give our new European customers the confidence in our connections that our customers around the world have had for more than 30 years.”
According to the SCI Assessed website, “SCI Assessed” is an established quality mark that is awarded to testify that manufacturers' technical data has been independently verified by SCI. The scheme provides reliability for the range of performance data offered by suppliers particularly where, for example, the product is new or the values are based on calculation methods outside the scope of established standards.
About Design Data
Design Data, a Nemetschek company, is a leading software innovator for the steel industry's fabrication, detailing and engineering sectors. SDS/2 software products provide automatic connection optimization, detailing, engineering information, fabrication data and much more, reducing the time required to design, detail, fabricate and erect steel. Founded in 1981 and headquartered in Lincoln, Nebraska, USA, the company serves customers in 17 countries. Information on Design Data and SDS/2 can be found at: www.sds2.com .
About SCI
SCI has been a trusted, independent source of information and engineering expertise globally for over 30 years, and remains the leading, independent provider of technical expertise and disseminator of best practice to the steel construction sector. SCI offers comprehensive advice, technical information, consultancy services and membership for manufacturers, engineers and designers for every aspect of steel construction.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170523005367/en/
Contact:
Design Data
Damon Scaggs, 402-441-4000
President
Fax:
402-441-4045
damon@sds2.com
www.sds2.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom